Data from Pharmawand - Curated by EPG Health - Date added 14 April 2018

Olita (olmutinib), a drug for non-small cell lung cancer, from Hanmi Pharmaceutical, has been withdrawn after the company abandoned the research program. Hanmi Pharmaceutical made this decision after it had struggled to recruit for its clinical trials and decided that the third-generation EGFR inhibitor was lagging too far behind its biggest rival, Tagrisso (osimertinib), from AstraZeneca, to be competitive.

This follows the Korean authorities investigating the company for not acting fast enough to disclose a fatality in a patient after treatment with Olita. There have also been issues with partners, as Boehringer backed out of a deal in 2016, and Chinese licensee Zai Lab returned its rights to the drug.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Related Content